Asta

Asta was founded in 2006 and listed on KOSDAQ in 2017 as a specialist in diagnostic instruments based on MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass spectrometry.

In 2015 the company became the third in the world to commercialize a MALDI-TOF device for medical microbial identification and built a bacterial database covering more than 5,000 species.

Its revenue mainly comes from sales of sample pretreatment systems, Data Generation Units, and diagnostic systems, followed by recurring consumables supply, database updates, and maintenance services.

Beyond medical microbial diagnostics (such as the IDSys LT), the company has broadened its application scope to veterinary disease diagnosis, cancer diagnosis, and industrial uses such as trace-contamination analysis in semiconductor and secondary-battery manufacturing.

Its subsidiary Northquest independently develops microbial-identification software and databases sold both domestically and abroad.

In 2021 the company launched OLED-material and secondary-battery analysis equipment, and in 2024 it developed a GM-TOF prototype for semiconductor process monitoring, expanding its industrial portfolio.

Through a joint venture established with Saudi Arabia's SIIVC, in which it holds a 20% stake, the company is also pursuing a Middle East manufacturing base. In February 2026, in vitro diagnostics company SD Biosensor signed a deal to acquire a 27.2% stake, putting a change of controlling shareholder in motion.

The company is also engaged in litigation with peer Rapigen over alleged utility-model infringement, adding a legal-risk dimension to the competitive landscape.

Consolidated revenue declined from KRW 3.35 billion in 2022 and KRW 3.13 billion in 2023, to KRW 3.35 billion in 2024, and then to KRW 2.59 billion in 2025.

The operating loss widened from roughly KRW -2.78 billion in 2022 and KRW -2.72 billion in 2023 to KRW -4.02 billion in 2024, before narrowing to KRW -2.59 billion in 2025. The operating margin deteriorated to -119.8% in 2024 before improving to -99.8% in 2025, though losses continued to exceed revenue.

The net loss attributable to owners widened from KRW -2.80 billion in 2022 to KRW -3.86 billion in 2024, then registered KRW -3.30 billion in 2025 (the 2023 figure was not disclosed).

Total equity fell from KRW 6.17 billion in 2023 to KRW 4.15 billion in 2024 before rising to KRW 9.22 billion in 2025, an increase that outpaced the net loss and is attributable to capital raised through share issuances.

The debt ratio surged to 106.4% in 2024 before falling to 67.9% in 2025, showing that capital injections helped repair the balance sheet.

On a quarterly basis, the company posted a rare operating profit of about KRW 36 million in the second quarter of 2025, but reverted to losses of KRW -504 million and KRW -484 million in the third and fourth quarters.

The first quarter of 2026 had the smallest revenue of the recent five-quarter window at KRW 464 million yet the largest operating loss at KRW -1.12 billion, while second-quarter 2026 revenue recovered to KRW 1.17 billion even as the operating loss reached KRW -839 million.

Operating cash flow was negative in all four years shown (ranging from roughly KRW -1.63 billion to KRW -4.03 billion), underscoring continued dependence on external financing to sustain operations.

The market for MALDI-TOF mass-spectrometry-based microbial identification is centered on hospitals, public health centers, and quarantine agencies, and its application has recently been expanding into industrial, food, and environmental fields.

The technology is regarded as a high-barrier deep-tech area because it requires not only hardware but also species-specific spectral databases, analysis algorithms, and validated clinical workflows.

As semiconductor and secondary-battery manufacturing processes become increasingly precise at the nanometer scale, demand for trace-contamination analysis is rising, expanding the industrial mass-spectrometry market alongside it.

In Korea's in vitro diagnostics market, large platform companies such as SD Biosensor, which hold diverse diagnostic portfolios spanning rapid immunoassay and molecular diagnostics, have been pursuing M&A to incorporate microbial-diagnosis technology.

Asta is classified as a holder of proprietary technology, having commercialized the world's third medical microbial-diagnosis MALDI-TOF device in 2015, though its revenue scale remains in the single-digit-billion-won range, limiting its absolute market standing.

The intellectual-property dispute with competitor Rapigen illustrates the competitive dynamics surrounding technology within Korea's microbial-diagnostics equipment market.

In the Middle East, a joint manufacturing base leveraging Saudi Arabia's state development fund (SIDF) is under construction, making emerging-market entry another variable in the industry cycle.

SD Biosensor described the acquisition as a strategic M&A intended to expand its diagnostics platform through deep-tech integration and secure a mid- to long-term growth engine.

Following the acquisition, the plan calls for combining Asta's microbial-diagnosis technology with SD Biosensor's existing portfolio of rapid immunoassay and molecular diagnostics to expand sales through cross-selling.

Asta's MALDI-TOF technology is expected to be supplied in stages as analysis equipment for semiconductor and secondary-battery processes, leveraging SD Biosensor's existing production, quality-control, and global distribution capabilities without requiring major new capital investment.

The Saudi Arabian joint venture has completed a SABIC review and site allocation and is under infrastructure construction targeting building completion in 2026, while pursuing SIDF funding in the second half of the year.

However, the procedure has been delayed, with the final payment date for the change-of-control transaction pushed back from the originally planned March 26, 2026 to September 30.

The company faces the task of passing a re-audit and securing additional liquidity within the listing-eligibility improvement period stemming from the audit opinion disclaimer, which runs until April 10, 2027.

SD Biosensor has stated it intends to maintain its existing acquisition plan despite the payment delay, suggesting the transaction itself is unlikely to be withdrawn.